Mature, real world progression-free survival (PFS) and overall survival (OS) milestones in stage IV, non-squamous, non-small cell lung cancer patients (nsqNSCLC) treated with first line pemetrexed(Pem)/platinum(Plat) followed by pem+/-bevacizumab(Bev) maintenance.

Parva Bhatt,Ibtihaj Fughhi,Sanjib Basu,Mary J. Fidler,Jeffrey A. Borgia,Philip Bonomi,Marta Batus

Mature, real world progression-free survival (PFS) and overall survival (OS) milestones in stage IV, non-squamous, non-small cell lung cancer patients (nsqNSCLC) treated with first line pemetrexed(Pem)/platinum(Plat) followed by pem+/-bevacizumab(Bev) maintenance.

2019

Parva Bhatt
Ibtihaj Fughhi
Sanjib Basu
Mary J. Fidler
Jeffrey A. Borgia
Philip Bonomi
Marta Batus

e20721Background: Pemetrexed maintenance therapy is associated with superior survival in stage IV nsqNSCLC patients. We have observed long term disease control in some patients treated with at leas...

Keywords:

Progression-free survival
Pemetrexed
Pathology
Bevacizumab
Disease
Maintenance therapy
Oncology
Squamous non-small cell lung cancer
Internal medicine
Medicine
stage iv
Lung cancer
overall survival
first line

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations